PDCD1 and non-small cell lung carcinoma: In this study, we established and validated a nomogram for NSCLC patients treated with anti-PD-1/PD-L1 plus bevacizumab to rapidly predict the long-term prognosis by combining simple clinicopathological factors and hematological indicators.